Oncology
Malignant tumors are a major type of disease that directly threatens human life. It has extremely complex occurrences, development, and pathological characteristics. Although there are various treatment alternatives, such as chemotherapy, targeted therapy, and immunotherapy, a cure or long-term survival is still out of reach for most patients, and there is a significant unmet clinical need for new therapeutic drugs and strategies. Chipscreen Biosesciences has dedicated two decades to research in this field. Chidamide, the company's first original innovative drug, is the world's first subtype-selective histone deacetylase (HDAC) oral inhibitor, classified as an epigenetic modulator with novel mechanisms. As of Jun. 2024, Chidamide has been approved for the treatment of peripheral T-cell lymphoma, breast cancer, leukemia, and diffuse large B-cell lymphoma (DLBCL).
Chipscreen Biosesciences is also developing innovative tumor therapies, including the multi-target, multi-pathway selective kinase inhibitor Chiauranib and the small-molecule PD-L1 inhibitor CS23546, both of which are currently in clinical trials.
Metabolic Diseases
Metabolic diseases are the most common chronic conditions, these conditions typically cause health problems often related to damage to blood cerebral vessels and vital organs, such as heart, liver and kidney, etc. Short-term efficacy from the medicine and lack of efficacious treatment are the main contributors to the waste of medical resources and poor prognosis, thus there is a strong ongoing demand for treatment for metabolic disorders.
Chiglitazar Sodium is the company's first drug for metabolic diseases and the world's first peroxisome proliferator-activated receptor (PPAR) pan agonist approved for treating type 2 diabetes. Its unique mechanism targets the core pathological mechanism of type 2 diabetes: insulin resistance. As a PPAR pan agonist, Chiglitazar Sodium can moderately activate all three PPAR subtypes, fully regulating glucose, lipid, and energy metabolism. This balanced approach enhances efficacy and safety while improving insulin resistance, offering promising prospects for the treatment of diabetes and metabolic syndromes. At present, the phase II clinical trial of Chiglitazar Sodium monotherapy for nonalcoholic steatohepatitis has met its primary efficacy endpoint, and research on compound preparations is progressing as planned.
Autoimmune disorders
Autoimmune disorders is a general category for a large group of conditions featuring over 100 pathological types, including common diseases such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, as well as various types of rare diseases. These conditions range in severity from minor impacts on quality of life to life-threatening. Due to the significant heterogeneity of pathological characteristics in different patients, clinical treatment tends to be ineffective, and in some cases no treatment exists. Therefore, new treatments are urgently demanded in the clinic.
Chipscreen Biosesciences has two candidates for autoimmune disorders in phase I clinical trials in China. CS12192, Chipscreen Biosesciences's first variety in this field and a JAK3/JAK1/TBK1 selective kinase inhibitor with a novel mechanism of action, is significantly different from existing clinical drugs in target selection and molecular mechanism. The phase I clinical study of CS12192 has been completed in China.
CS32582 is a highly selective small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2) independently developed by Chipscreen Biosesciences. In preclinical studies, CS32582 showed significant therapeutic effects in mouse models of psoriasis, and the phase I clinical trial is currently ongoing in China.
Viral Diseases
With the advancement of globalization, public health security is being endangered seriously by known and unknown viral infections, and viral infectious diseases will become one of the most threatening diseases to human beings in the future. The most significant difficulties for current antiviral therapies lie in insufficient treatment, easy drug resistance, and easy rebound after discontinuation. Developing high-efficacy and low-resistance specific or broad-spectrum antiviral drugs helps to deal with existing known viral infectious diseases actively, and such drugs can serve as a technical reserve of the antiviral treatment system to resist unknown virus risks.
With regard to hepatitis B virus (HBV), we have started the R&D of drugs with different mechanisms of action, so as to address existing unmet clinical needs and achieve the long-term goal of functional cure in the future.
Central Nervous System Diseases
Central nervous system diseases refer to a large category of cognitive and motor dysfunction diseases that directly affect the quality of life and mental health of humans, which mainly include neurodegenerative disorders represented by Alzheimer's disease, psychiatric diseases represented by major depressive disorder, and other sensory and motor disorders such as epilepsy, pain, and spinal nerve damage. Considering the complex mechanism of central nervous system diseases, the slow preclinical pathological process, and the difficulty in timely intervention and treatment, such diseases have become a key and pressing area of global drug R&D.
For Alzheimer's disease, Chipscreen Biosesciences not only targets mainstream mechanisms and targets such as β-amyloid plaques, tau phosphorylation, and acetylcholinesterase, but is also advancing the development of new drugs that address differentiated mechanisms. These efforts are informed by human genetic associations and real-world epidemiological and objective evidence of Alzheimer's disease epidemiology, aiming significantly impact in the field.